<DOC>
	<DOCNO>NCT01551329</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ketamine reduce depressive symptom subject comorbid major depressive episode alcohol dependence . The investigator hypothesize follow present study : A single dose ketamine induce rapid , robust sustain reduction depressive symptom subject comorbid major depressive episode alcohol dependence relative placebo define change Hamilton Depression Rating Scale total score 72 hour post infusion . A single dose ketamine deliver safely , minimal adverse event complication , subject comorbid major depressive episode alcohol dependence .</brief_summary>
	<brief_title>Ketamine Depression Alcohol Dependence</brief_title>
	<detailed_description>Major depression alcohol dependence within ten disorder high worldwide disease burden identify World Health Organization ( WHO ) , disorder frequently co-occur , especially high-service utilizing patient severe persistent mental illness . Currently available treatment inadequate chronic condition alone , inadequacy even clear people meet criteria disorder . Ketamine first report rapidly-acting antidepressant 2000 via research occur Yale , , since time , several small randomize controlled trial , single subanesthetic dose intravenous ketamine demonstrate efficacy improve mood unipolar bipolar depression within hour administration . These effect last least week . Interestingly , ketamine demonstrate produce robust effect treatment-refractory unipolar depressed subject family history alcoholism relative similarly difficult-to-treat subject without family history alcohol problem . In addition , recently-detoxified alcoholic safely administer subanesthetic dos ketamine , , infusion , alcoholic ( even family history alcoholism ) display differential response ketamine , e.g . blunt psychotic-like cognitive effect , relative healthy control . Therefore , ketamine may reduce depressive symptom alcohol consumption compare placebo patient comorbid major depression current alcohol dependence . Positive result mark major advance clinical care treat condition open door scientific investigation clinical neuroscience highly comorbid prevalent condition . This two phase , double-blind , randomize , placebo-controlled , cross-over , proof-of-concept study design determine effect single dose ketamine , administer IV , mood alcohol consumption , psychotropic medication-free patient meet DSM-IV-TR criterion major depressive episode ( MDE ) current alcohol dependence . Participants assign randomly receive either intravenous ketamine ( 0.5mg/kg ) saline solution 2 week apart cross design . The ketamine dose base previous study patient depression bipolar disorder . A team member experience ketamine infusion administer study medication 40-minute infusion blind fashion Biological Studies Unit WHVA . 20 depressed alcohol dependent subject age 21-65 recruit study advertise West Haven VA clinic . Subjects complete informed consent process thoroughly screen inclusion exclusion criterion describe . Individuals give post consent test evaluate understanding procedure . For subject provide incorrect answer test item , research staff review correct answer subject show subject correct answer find consent form . Those get 60 % question wrong still unable understand procedure review research staff exclude study . They refer appropriate resource outpatient treatment depression alcoholism . Before start study patient free psychotropic medication .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>1 . Male female ( postmenopausal , surgically sterile negative pregnancy test screening agreement utilize medicallyapproved birth control method include complete abstinence test period ) age 21 65 year old . 2 . Able provide write informed consent accord WHVA Yale HIC guideline . 3 . Medically neurologically healthy basis medical history , physical examination , EKG , screen laboratory ( CBC w/ differential , basic metabolic profile include BUN/creatinine , TSH , fT4 , AST , ALT , GGT , total protein , albumin , vitamin B12 , folate , VDRL , HIV , hepatitis B C , urinalysis , HCG , urine toxicology screen ) . Predefined exclusion criterion identify , e.g . LFTs &gt; 3x upper limit normal . Individuals stable medical problem direct CNS effect , e.g . hypertension diabetes mellitus , interfere medication administer , e.g . oral hypoglycemics , may include medication adjust month prior study enrollment . 4 . Current DSMIVTR major depressive episode ( MDE ) structure clinical interview ( SCID ) MADRS score ¬ &gt; 20 . 5 . Current DSMIVTR alcohol dependence one heavy drinking day ( &gt; 4 standard drinks/session men &gt; 3 standard drinks/session woman ) last 3 week . 6 . Abstinent drinking &gt; 5 day prior receive ketamine . 7 . No current psychotropic medication ( exclude benzodiazepine alcohol detoxification need ) last 2 week ( 4 week fluoxetine ) . 8 . Individuals complete detoxification program least 5 day past last drink . 1 . Unstable medical condition medical problem know CNS effect , e.g . uncontrolled hypertension ( SBP≥170 and/or DBP≥100 ) confirm history alcoholwithdrawal seizure . 2 . Active suicidal ideation , intent plan . 3 . Active DSMIVTR substance use disorder past three month ( alcohol nicotine use disorder ) . 4 . Prior diagnosis DSMIVTR psychotic spectrum disorder , e.g . schizophrenia , schizoaffective disorder , bipolar I d/o psychotic feature , MDD psychotic feature .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>depression</keyword>
	<keyword>alcohol</keyword>
	<keyword>comorbidity</keyword>
	<keyword>ketamine</keyword>
	<keyword>glutamate</keyword>
	<keyword>NMDA</keyword>
</DOC>